Currency In USD
| Previous Close | 3.16 |
| Open | 3.17 |
| Day High | 3.31 |
| Day Low | 2.96 |
| 52-Week High | 7.75 |
| 52-Week Low | 2.9 |
| Volume | 164,249.91 |
| Average Volume | 261,693 |
| Market Cap | 207.4M |
| PE | -1.4 |
| EPS | -2.36 |
| Moving Average 50 Days | 4.08 |
| Moving Average 200 Days | 4.32 |
| Change | 0.14 |
CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 1:00 PM GMT
CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upre
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
GlobeNewswire Inc.
Dec 18, 2025 12:10 PM GMT
CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or the “Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upre
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
GlobeNewswire Inc.
Dec 18, 2025 12:00 PM GMT
Collaboration to leverage CAMP4’s RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases CAMP4 to receive $17.5 million upfront and eligible for additional milestone-based payments,